Targeted Capacity Expansion: Medication Assisted Treatment - Prescription Drug and Opioid Addiction (Short Title: MAT-PDOA) | TI 17 017

Opportunity Information: Apply for TI 17 017

The Targeted Capacity Expansion: Medication Assisted Treatment - Prescription Drug and Opioid Addiction (MAT-PDOA) grant was a FY 2017 discretionary funding opportunity from the Department of Health and Human Services, administered through SAMHSA's Center for Substance Abuse Treatment. Its central goal was to expand and strengthen access to medication-assisted treatment (MAT) for people with opioid use disorder who are seeking care or already engaged in MAT, with a strong emphasis on improving both treatment reach and treatment quality in areas most affected by opioid and heroin addiction.

A key feature of this program was its targeted focus on the states experiencing the greatest opioid burden. SAMHSA directed this funding to states identified as having the highest per-capita rates of primary treatment admissions for heroin and opioids, as well as states showing the sharpest increases over time, using SAMHSA's Treatment Episode Data Set (TEDS) trends from 2007 through 2014. In other words, this was not a general nationwide expansion program; it was designed to concentrate resources where treatment demand and opioid-related harm were most intense or rising fastest.

The grant framed MAT as more than simply prescribing medication. For this opportunity, MAT specifically included FDA-approved medications used to treat opioid use disorder, including opioid agonist therapies like methadone and buprenorphine (including both combination buprenorphine/naloxone products and mono-product formulations), and an opioid antagonist option, extended-release injectable naltrexone. SAMHSA emphasized that medication should be delivered alongside behavioral therapies and other clinical supports to reduce relapse risk and support long-term recovery.

SAMHSA also defined "integrated care/treatment" as an important program expectation and outcome area. Integrated care, in this context, meant organized delivery and coordination of medical services (including the MAT medications themselves) with behavioral health care, social services, peer supports, and other recovery services for patients with multiple needs. The intent was to improve overall health outcomes by connecting what are often fragmented services into a more coordinated treatment experience, rather than treating medication and counseling as separate or loosely connected components.

The FOA highlighted core service elements that grantees were expected to provide or strengthen as part of MAT expansion. These elements included screening and assessment (including evaluating opioid use disorder severity, physical dependence, and whether MAT is clinically appropriate), ongoing case management, and comprehensive opioid use disorder treatment services such as counseling and behavioral therapies. The program also acknowledged that some clients may need medication support for co-occurring alcohol use disorder, signaling an expectation that programs address co-occurring conditions when clinically indicated rather than treating opioid use disorder in isolation.

The desired outcomes were clearly tied to measurable changes in access, integration, and substance use behavior. SAMHSA sought (1) an increase in the number of admissions for MAT, meaning more people entering medication-supported treatment; (2) an increase in the number of clients receiving integrated care/treatment, meaning more clients benefiting from coordinated medical, behavioral, and recovery supports; (3) a reduction in illicit opioid use at a six-month follow-up point; and (4) a reduction in non-prescribed use of prescription opioids at six-month follow-up. These outcomes reflect both system-level goals (expanding capacity and integration) and patient-level goals (reduced illicit and nonmedical opioid use over time).

From a funding and administrative standpoint, the opportunity was listed under CFDA 93.243 (health-related programming) and offered grants with an award ceiling of $2,000,000. SAMHSA anticipated making about five awards under this FOA. The funding opportunity number was TI-17-017, it was posted on May 31, 2017, and the original application closing date was July 31, 2017. Eligibility was described broadly as "others" with additional clarification referenced in the FOA's eligibility section, implying that applicants needed to consult the full announcement for precise eligibility requirements and any state- or entity-specific limitations.

Overall, MAT-PDOA was designed as a targeted, outcomes-driven investment to rapidly expand evidence-based opioid treatment capacity in the hardest-hit jurisdictions, while pushing programs toward coordinated, person-centered care that combines FDA-approved medications with counseling, case management, and recovery supports to improve six-month substance use outcomes.

• The Department of Health and Human Services, Substance Abuse and Mental Health Services Adminis in the health sector is offering a public funding opportunity titled "Targeted Capacity Expansion: Medication Assisted Treatment - Prescription Drug and Opioid Addiction (Short Title: MAT-PDOA)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.243.
• This funding opportunity was created on May 31, 2017.
• Applicants must submit their applications by Jul 31, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $2,000,000.00 in funding.
• The number of recipients for this funding is limited to 5 candidate(s).
• Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).

Apply for TI 17 017

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: